CytRx falls after arimoclomol put on hold

CytRx (NASDAQ:CYTR) fell $0.49 (23%) to $1.60 on Tuesday after it said FDA placed a hold on a Phase IIb trial of arimoclomol to treat amyotrophic lateral sclerosis (ALS). FDA requested additional anal...